Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A

Masato Chiba(Kindai University Sakai Hospital), Kazuto Nishio(Kindai University Sakai Hospital)

BMC Cancer

April 19, 2017

10.1186/s12885-017-3263-z

Cited by 38

Related Papers

Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

|Science Translational Medicine|2011|670

Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment

|Annals of Oncology|2017|294

B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity

|Clinical Cancer Research|2018|169

Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site

|Journal of Clinical Oncology|2019|168

Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung Cancer

|Clinical Cancer Research|2012|156